JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
Peter A. Thompson, a director at Sionna Therapeutics , Inc. (NASDAQ:SION), has made significant stock acquisitions as reported in a recent SEC filing. Thompson purchased 550,000 shares of common stock at a price of $18 each, totaling $9.9 million. These shares were acquired during the company’s initial public offering on February 10, 2025. The stock now trades at $22.24, representing a 23.6% premium to the IPO price, with average daily trading volume of 1.02M shares. InvestingPro subscribers can access detailed insider trading patterns and comprehensive trading metrics to make more informed investment decisions.
The transaction increased Thompson’s total holdings to 3,704,959 shares. Additionally, the filing noted the conversion of Series B and C convertible preferred stock into common stock, although these transactions did not involve any cash exchange. The shares are held indirectly through OrbiMed Private Investments VIII, LP, reflecting Thompson’s continued investment interest in the pharmaceutical company. Since its IPO, SION has traded in a range of $21.10 to $25.19, showing relatively stable price action despite the broader market volatility.
In other recent news, Sionna Therapeutics has made significant changes to its corporate bylaws and articles of incorporation. This move comes after the company’s recent initial public offering (IPO), as stated in a filing with the Securities and Exchange Commission. The updated certificate authorizes the issuance of 500 million shares of common stock and 10 million shares of undesignated preferred stock. The new bylaws have also removed all references to the previously existing series of preferred stock and have revoked the stockholders’ ability to act by written consent instead of a meeting or to call special meetings. Moreover, the amended bylaws establish an advance notice protocol for stockholder proposals and nominations for the board of directors. These changes are part of Sionna Therapeutics’ transition to a publicly traded entity and reflect the standard practices for companies listed on major stock exchanges. These are some of the recent developments at Sionna Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.